New research signals a major shift in how pneumonia is treated in young children, offering a safer, cost-effective, and more efficient model for African health systems.
Makerere University Lung Institute (MLI) has unveiled transformative findings from a multi-country clinical trial that could redefine how childhood pneumonia is treated in African hospitals. Announced ahead of the institute’s upcoming 10-year anniversary in November 2025, the results of the PediCAP clinical trial offer compelling evidence that young children suffering from severe community-acquired pneumonia can safely switch from injectable to oral antibiotics earlier than current global guidelines suggest. This approach not only shortens hospital stays but also reduces treatment costs and minimizes the risk of antibiotic overuse.
The study—conducted between 2020 and 2023 in Uganda, South Africa, Zambia, Zimbabwe, and Mozambique—enrolled over 1,100 children aged 2 months to 6 years. It was led by Dr. Victor Musiime, a pediatric infectious disease specialist based at Makerere University.
Also, read about Makerere Admissions
What does Makerere say about Childhood Pneumonia?
“Our results show that it is both safe and effective to switch from injectable to oral antibiotics once a child begins to improve,” Dr. Musiime said in a press briefing. “We also found that shorter courses—four or five days—are just as effective as the standard five-day regimen recommended by the World Health Organization (WHO).”
These findings challenge longstanding WHO protocols that mandate five full days of intravenous or injectable antibiotic treatment for severe pneumonia. In practice, these guidelines often lead to prolonged hospital stays, increased healthcare costs, and strained family resources.
The PediCAP trial introduces a simpler, community-friendly alternative. By allowing a faster transition to oral antibiotics such as amoxicillin—an affordable and widely available option—hospitals can discharge recovering children earlier without compromising outcomes.
A Critical Breakthrough for Africa
Pneumonia remains the leading infectious cause of death among children under five in sub-Saharan Africa, accounting for thousands of preventable deaths each year. The burden is exacerbated by limited hospital capacity and the rising threat of antimicrobial resistance.
Dr. Damalie Nalwanga, a pediatrician and co-investigator on the trial, highlighted the wider implications: “This approach frees up beds for other critical patients and reduces unnecessary antibiotic exposure. It’s safer, cheaper, and ultimately better for both children and healthcare systems.”
In a region where access to quality healthcare is often limited by infrastructure and economic constraints, these findings are particularly significant. The trial’s success underlines the power of African-led, collaborative research in producing data-driven, context-specific health solutions.
Collaboration, Innovation, and Local Impact
Dr. Rebecca Nantanda, Deputy Director at MLI, praised the study as a landmark in African clinical research.
“This is a shining example of what we can achieve when we invest in science that reflects our own challenges and strengths,” she said. “The PediCAP trial will directly improve the lives of African children, and it proves that high-impact, high-quality research can be done here at home.”
Beyond its clinical findings, the trial also revealed that amoxicillin performs just as well as the more expensive combination antibiotic amoxicillin-clavulanate. This discovery further strengthens the case for cost-effective, scalable treatment models—critical for resource-limited health systems.
Looking Ahead: A New Standard of Care
As MLI gears up to celebrate a decade of leading respiratory health innovation in Africa, the success of the PediCAP trial stands as a milestone in its growing legacy.
“MLI is proud to be at the forefront of child health research,” said Dr. Nantanda. “But this is just the beginning. We’re looking ahead to the next decade with even greater ambition and commitment.”
The findings are expected to inform future updates to national and international treatment guidelines, potentially transforming pneumonia care across Africa and beyond.
For families, clinicians, and health policymakers, the message is clear: A safer, faster, and more affordable pneumonia treatment pathway is not just possible—it’s here.
